ã¦ã£ãºã³ããã®ä¸å¹³çãªã¹ã¯ãé¡èåããæ¥æ¬
ã¯ããã«
ãªãã¯ãã³å¤ç°ä½BA.5äºç³»çµ±ã«ãã第7æ³¢æµè¡ã¯ãä¸å¹¸ã«ãã¦æ¥æ¡å¤§ããç ç²è ãå¢ããç¶ãã¦ãã¾ããããã¯ãã¦ã£ãºã³ããæ¦ç¥ã«ãããä¸å¹³çãªã¹ã¯ããæ¿åºãçºæ¿è ã®ä¸ä½çºã«ãã£ã¦ãããã¦æ å½å°éå®¶ã«ããèªç¥ãã¤ã¢ã¹ã«ãã£ã¦é¡èåããçµæã¨èãããã¾ãããã®ããã°è¨äºã§ããã説æããªãããç¾æ³ãèå¯ãããã¨æãã¾ãã
1. ä¸å¹³çãªã¹ã¯ã¨ã¯
ã¦ã£ãºã³ããã®ä¸å¹³çãªã¹ã¯ã¨ã¯ãä¸ã¤ç®ãå人ã®çµæ¸é¢ã§ã®ä¸å¹³çãäºã¤ç®ã¯ç æ°ã社ä¼ã«åã¼ãå½±é¿ã®åããããã¦ä¸ã¤ç®ã¨ãã¦ç æ°ãå人ã«åã¼ãå½±é¿ã®åããå«ããã®ã§ããã¤ã¾ããCOVID-19ã¯ãã¹ã¦ã®äººãã¡ã社ä¼åéãæ¥ç¨®ãªã©ã«åçã«æªå½±é¿ãåã¼ãã¦ããã®ã§ã¯ãªããçµæ¸çå¼±è ãç æ°ã®é¢ã§ã®èå¼±è ã«ããéä¸çã«æªå½±é¿ãåã¼ãã¦ããã¨ãããã¨ã§ãã
è±å½ã®å¥åº·è²¡å£ï¼Health Foundationï¼ã®ããããã»ãã£ã³ãï¼David Finchï¼ã¯ãã¦ã¤ã«ã¹ã®èå»¶ãæããããã«ä¸è¬äººã«å人çãªè²¬ä»»ãæå¾ ãããã¨ã¯ãçµæ¸çæ¯æ´ãä¸ååãªå¤ãã®äººã ãææããã¾ã¾ç¤¾ä¼ã«åºã¦ãã¾ãå±éºæ§ãç¡è¦ãã¦ããã¨è¿°ã¹ã¾ãããè±å½ã®ã¦ã£ãºã³ããæ¦ç¥ã¯ãCOVID-19ãããã¾ã§ã«ç¤¾ä¼å ¨ä½ã«åã¼ããä¸å¹³çãªå½±é¿ã¨ã"ã³ããã¨ã¨ãã«çãã "ãã¨ã«ããä¸å¹³çãªãªã¹ã¯ï¼unequal risks from âliving with covid"ï¼ãèªèãããã¨ãããã³ããã«åãããã¨ã«ã失æãã¦ãããã¨ä¸»å¼µãã¦ãã¾ã [1]ã
çµæ¸çä¸å¹³çãªã¹ã¯ã®é¢ããè¨ãã°ãæ¥æ¬ã§ã¯å½æ°å ¨å¡ã«10ä¸å給ä»ãªã©ã®äºä¾ã¯ããã¾ããããçµæ¸çå¼±è ã§ãã人ãã¡ãçµæ¸åºç¤ãèå¼±ãªä¸å°ä¼æ¥ã«å¯¾ããçµæ¸è£åãçµæ¸æ¯æ´ã¯ååã§ããã¨ã¯è¨ãé£ãç¶æ³ã§ãããã³ãããã¯æéã§æ¥æ¬å ¨ä½ã§èªæ®ºè ãå¢å ããå¾åã¯è¦ããã¾ãããã女æ§ãè¥ã人ã«éã£ã¦ã¿ãã¨å¢å ã®å¾åãããã¨ããå ±åãããã¾ã [2] ããã®çç±ã¨ãã¦ãèªæ®ºè ãå¢ãã¦ããªãä»ã®å½ã§ååãªæ¯æ´ãåãããã¦ãã䏿¹ãæ¥æ¬ã§ã¯çµæ¸çå¼±è ã«æ¯æ´ãè¡ãå±ãã¦ããªãã®ã§ã¯ãªããã¨ææããã¦ãã¾ãã
çµæ¸çå¼±è ã¯ãçæ´»ã®ããã«ã¯ããã¨ãææãªã¹ã¯ãé«ãå ´åã«ããã¦ãåããããå¾ãªãç¶æ³ã«ããã¾ãããã®é¢ã§ãçµæ¸çå¼±è ã®æ¯æ´ã¨å ¬è¡è¡ç対çã¯ä¸ä½åãããã®ã¨èããã¹ãã§ãããã
SARS-CoV-2ææã¯ãå¤ãã®ç¡çç¶è ãçç¶ã®è»½ãï¼ããããå£ç¯æ§ã¤ã³ãã«ã¨ã³ã¶ä¸¦ã¿ã®ï¼äººãã¡ãçãã䏿¹ã§ãç æ°ã®ãªã¹ã¯ã¯é«é½¢è ãåºç¤ç¾æ£ãæãã人ãå ç«ä¸å ¨è çã®èå¼±è ã«å¯¾ãã¦èããé«ããªããã¨ãç¥ããã¦ãã¾ãããã®ãã³ãããã¯ã®å¯¾çã®ç¦ç¹ã¯ãå½åãããããã®èå¼±è 対çã§ããããªãã¯ãã³æµè¡ã«ãªã£ãç¾å¨ã§ãå¤ããã¾ãããç±³CDCãããããã®èå¼±è ã®ãªã¹ã¯ãæå°åããã®ãèã ã¨è¨ã£ã¦ãã¾ãï¼âCOVID-19ã¤ã³ãã¯ãã®æå°åã¼ç±³CDCã¬ã¤ãã©ã¤ã³ï¼ã
æ¥æ¬ã®é«é½¢åçï¼65æ³ä»¥ä¸ã®å ¨äººå£ã«å ããå²åï¼ã¯28.7%ã§ä¸çãããã§ããã2ä½ã®ã¤ã¿ãªã¢ï¼23.6%ï¼ã大ããå¼ãé¢ãã¦ãã¾ããä»ã®G7諸å½ã§ã¯ãé ã«ã6ä½ãã¤ãï¼22.0%ï¼ã14ä½ãã©ã³ã¹ï¼21.1%ï¼ã30ä½è±å½ï¼18.9%ï¼ã31ä½ã«ããï¼18.6%ï¼ã39ä½ç±³å½ï¼17.0%ï¼ã¨ç¶ãã¦ãã¾ã [3]ã
ãã®æå³ã§ãæ¥æ¬ã¯æãã³ãã対çã«æ°ãã¤ããªããã°ãããªãã¯ãã§ãããæ®å¿µãªãã第7æ³¢ã§æ»äº¡è æ°ãæ¥æ¡å¤§ãã¦ãããç¾å¨ãæ»äº¡è æ°ãæ»äº¡çã¨ãã«ä¸çä¸ä½ã¯ã©ã¹ã«ãªã£ã¦ãã¾ãï¼å³1ï¼ã
å³1. æ¥æ¬ãéå½ããã³æ¬§ç±³å é²å½ã«ãããCOVID-19ã®æ»äº¡è æ°ï¼ä¸ï¼ããã³æ»äº¡çï¼äººå£æ¯æ»è æ°ãä¸ï¼ã®æ¨ç§»ï¼Our World in Dataãã転è¼ï¼.
䏿¹ã§ãè±å½ã¯é«é½¢åçã§ä¸ç30ä½ã¨ããæ¯è¼çä½ãæ°´æºãªã®ã«ãæ¥æ¬ã¨åæ§ãæ»äº¡è ã¨ããææ¨ã§ä¸çã®ãããã¯ã©ã¹ã«åãé£ãã¦ãã¾ããããã¯ãå¾è¿°ã®ããã«ãã¦ã£ãºã³ããã®ä¸å¹³çãªã¹ã¯ãè¦å¶å ¨é¢è§£é¤ã«ãã£ã¦é¡èåããä¾ã ã¨èãããã¾ãã
2. ä¸å¹³çãªã¹ã¯ã®ç¡çè§£
2-1. éçè éè¦ã¨ãããã¤ã¢ã¹
æ°åã³ããã¦ã¤ã«ã¹ææç対çåç§ä¼ã®å°¾è¦èä¼é·ãå»çå°éå®¶ãã¡ã¯ãäºãããã¨ã«ææè æ°ããããéçè æ°ãéè¦ãã¨è¨ã£ã¦ãã¾ãããç§ã¯ãããèãã¦ãã¦ãå ¨ãä¸é©åãªçºè¨ã ã¨æãã¦ãã¾ããããªããªãããã³ãããã¯å¯¾çã¯ãå è¡ææ¨ã¨ãã¦ã®ææè æ°ãææ¡ããªãããèå¼±è ã«å¯¾ãããã®å½±é¿ãã©ãã ãæå°åããã®ãæéè¦ã§ããããã®é¢ããã¿ãã¨ãéçè ãéè¦ãã¨ããã®ã¯çå¤ãã®æãããããã§ãã
éçè ã¯æææµè¡ã«é ãã¦çãããã¨ã¯å¨ç¥ã®äºå®ã§ãããéçè ã®ç æ ãæ£è ã«ãã£ã¦ãããã¦æµè¡ãã¦ã¤ã«ã¹å¤ç°ä½ã«ãã£ã¦ãå¤ãã£ã¦ãã¾ããéçè ã ãã«ç®ãåããã¦ããã¨å¯¾çãé ãããã¤ä¸å®ã®åºæºã§éçè ãæ¬ããããã¨ã«ãããããã«è¢«å®³ã®å®æ ããããé¢ãã夿ãã¹ã«ãªã£ã¦ãã¾ãã®ã§ãã
ä»ã®éçè ã®åºæºã¯ããã«ã¿ä»¥åã®èºçãèµ·ããã¦äººå·¥å¼å¸å¨ãECMOãè£ çãããæ£è ã«åºã¥ãã¦ãã¾ããæ¿åºç³»åç§ä¼ãèªæ²»ä½ã®ã¢ããã¤ã¶ãªã¼å§å¡ä¼ããéçè ãéè¦ãã¨è¨ãã°ãè¡æ¿ã¯ãã®åºæºï¼å®ç¾©ï¼ã«åºã¥ãã¦ãã£ããéçè ãã«ã¦ã³ããã¾ããã¨ãããããã®åºæºããå¤ããã°ãã©ãã ãé篤åããããéçè ã§ã¯ãªãã¨ãããã¨ã«ãªã£ã¦ãã¾ãã¾ãã
仿ã®ãã¬ãçªçµã§ã¯ããã®ä¹é¢ã®å®æ ã示ããã¦ãã¾ãããããªãã¡ã大éªåºã®ç¬¬6波以éï¼ãªãã¯ãã³æµè¡ï¼ã®æ»è æ°2168äººã®æ»äº¡å²åãè¦ãã¨ãç´9å²ã軽çãä¸ççããçºçãã¦ãããéçè ã¯1å²ã«ããéããªãã®ã§ãã
å³2.
å³1ã§ç¤ºããæ¥æ¬ã«ãããæ»äº¡è æ°ã®æ¥å¢ãããã®å¤æãã¹ããèµ·ãã£ã¦ããã¨ãããæããããã¨ã§ãããã¬ãã§é¡ãªãã¿ã®å°éå®¶ããå»çç¾å ´ã«è¦åã£ãéçè ã®åºæºããã¡ãã¨ä¿®æ£ãããã¤å è¡ææ¨ã§ããææè ã®å ¨æ°ææ¡ã«åºã¥ãã¦ãèå¼±è 対çãã¨ãããã«æè¨ãã¦ããã°ãããã»ã©ã®æ»äº¡è æ¥å¢ã«ãªããªãã£ãããããã¾ããã
éçåäºé²ã®è¬ã¨ãã¦ã¯ã¢ã«ããã©ãã«ããã¯ããããããããé«é½¢è ææè ãåºç¤ç¾æ£ãæããææè ã«ä½¿ããã¨ãã§ãã¾ãããå®éã«ã¯æè¬ã®ã¿ã¤ãã³ã°ã¨å¶éã®åé¡ãæ±ãã¦ãã¾ãããããã¯çºçãã5æ¥ä»¥å ã«å¦æ¹ããã¨ããã®ãæ¡ä»¶ã§ããããã®ããã«ã¯ããã¨ã軽çã§ãã£ãã¨ãã¦ãæ©æã®æ¤æ»ã¨è¨ºæãå¿ è¦ãªã®ã«ãå»çå´©å£ã®ä¸ã§å¿ ããããã¾ããã£ã¦ãã¾ããããããããããã¯å½ã管çãã¦ããè¬ã§ãããçºç±å¤æ¥ã®ã©ãã§ã使ããã¨ãããã®ã§ã¯ããã¾ããã
ç¾å®ã¯ãéçè ã大äºã¨è¨ããªãããä¸å¹³çãªã¹ã¯ã®ä¸ã¤ã§ãããèå¼±è ã¯èª°ããã¨ãããã¨çã«ç®ãåãããããå»çé¢ã§ããã¾ã対å¿ããã¦ããªãã¨ãããã¨ã«ãªãã§ãããã
2-2. å°éå®¶ã®èªç¥ãã¤ã¢ã¹
æ å½å°éå®¶ã¯ãæªåããææç¶æ³ã«å¯¾ãã¦ã¯ãæå¹ãªå¯¾å¿çã®æè¨ã®å¿ è¦æ§ã«è¿«ããã¾ãããã®ããã«ãã¦ãä¸çæ¸å½èãããã¨ããçµæãããã£ã¦è³ã®èª¤ä½åï¼ãã°ï¼ãèµ·ãã£ãããæ³å®å¤ã®ãã¨ãéãªã£ãããéå¢ã«è¿½ãè¾¼ã¾ããã¨ããã¬æ¹åã¸çµè«ãå°ããããã¾ãã
ãã®ãããªèªç¥ãã¤ã¢ã¹ã¨æããããã¨ããæ¿åºç³»å°éå®¶ã§ãèµ·ãã£ã¦ãã¾ããå æ¥ãå°éæå¿ã¯ãæ°åã³ããã®åºå£æ¦ç¥ãã«é¢ããæè¨ï¼ããããé¿åæè¨ï¼ãè¡ãªãã¾ããããã©ããã©ãåéãããã®ãããã®ãã³ãããã¯ä¸ã§ææªã®æµè¡ç¶æ³ã«ããã«ãããããããCOVID-19ããå½ããåã®ç æ°ãã¨ãã¦èããã¨ã³ãããã¯ã¸ã®éçãæç¤ºããã®ã§ãã
COVID-19ãã¨ã³ãããã¯ã«ãªãã¨ããç§å¦çæ ¹æ ã¯ä¾ç¶ã¨ãã¦ããã¾ããããæ¬§ç±³ãå ããã¦å°å ¥ããå ¨é¢è§£é¤ã®ã¦ã£ãºã³ããæ¦ç¥ãçä¼¼ãã¦ããèªåçã«ã¨ã³ãããã¯ã«ãªãã¯ããããã¾ãããå é²å½ã®é¸æãç¡æ¹å¤ã«ç¡é²åç¶æ ã§å°å ¥ãã¦ããæ¥æ¬ããã¾ãããã¯ãããªããã¾ãã¾ã被害æ¡å¤§ãããã ãã§ãããï¼âèµ·ããã¹ããã¦èµ·ãã£ãå»çå´©å£ãããã¦å°éå®¶æå¿æè¨ã®ç¡å³ä¹¾ç¥æï¼ã
ãã®é¿åæè¨ã«ã¯ããããããã³ãããã¯ã¨ããæ¦å¿µãæãã¦ããã®ã§ãCOVID-19ã®èå¼±è ãä¸å¹³çãªã¹ã¯ã«ã¤ãã¦ã¯ãå ¨ã念é ã«ãªãããã§ãã
æµ·å¤ã§ããå ¨é¢è§£é¤ã§ææå¶å¾¡ãªãã«ãªã£ã¦ããè±å½ã¨ãä¾ç¶ã¨ãã¦è å¨ã¨ãã¦èãã¦ããç±³å½ï¼âCOVID-19ã¤ã³ãã¯ãã®æå°åã¼ç±³CDCã¬ã¤ãã©ã¤ã³ãç±³CDCã¬ã¤ãã©ã¤ã³ã¨withã³ããï¼ã®éã§ãè¦è§£ãè·¯ç·ã®å·®ãããã¾ãã
ãã®ãããªå°éå®¶ã«ããèªç¥ãã¤ã¢ã¹ãæå³çãªèªå°ã誤謬çã«ãã£ã¦ãæ¿åºã社ä¼ãã¡ãã£ã¢ã«å¤§ããªå½±é¿ãåã¼ãã¦ããã¨è¨ããã§ãããããã¡ãã¡ããèããã¦ãããã³ããã¯è»½çãããå£ç¯æ§ã¤ã³ãã«ã¨ã³ã¶ä¸¦ã¿ããã2é¡ãã5é¡ã¸ãããå ¨æ°ææ¡ã¨ãããããªã©ã®å£°ã¯ããã®å½±é¿ãåãããã®ã§ããããã¾å«ç·ã®èª²é¡ã§ãã第7æ³¢æææ¡å¤§ã®æå¶ã«ã¯ä½ã®å½¹ã«ãç«ã¡ã¾ããã
2-3. æ¿åºã¨çºæ¿è ã®åéã
éå»ã®ãã³ãããã¯ã®ä¸ã§ææªã®æµè¡æ³¢ãè¿ããæ®µéã§ãå ¨é¢è¦å¶è§£é¤ãããå½ã¯ããã¾ãããããã¯ãã¦ã³ããããªããä½ããã®é¨åçãªéå»è¬çä»å ¥ã¨å ¬è¡è¡çã®åãçµã¿ãè¡ãªã£ã¦å¯¾å¦ãã¦ãã¾ããã䏿¹ã§ãæ¥æ¬ã¯é廿æªã®BA.5æµè¡ã«ãªã£ã¦ããã®ã«ãå²¸ç°æ¿æ¨©ã¯è¡åå¶éãªãã¨ããæ¹éãæã¡åºãã¾ãããä½ã¨ãããã°ãã°ãã§ããããåå½ãè¦å¶ç·©åããä¸ã§ãèªåãã¡ãããã§è¡ããã¨åéãããã®ã§ããããã
第6æ³¢ã¨æ¯ã¹ã¦ç¬¬7æ³¢ã¯2å以ä¸ã®æ°è¦ææè æ°ã®çºçã«ãªã£ã¦ãã¾ãããã®éãã¯ä½ã§ããããããã¡ãããããããæµè¡ã®ä¸»ä½ãBA.1/2åã¨BA.5åã¨ãããªãã¯ãã³äºç³»çµ±ã®éããããã¾ããï¼ä¼æåãå¾è ãåè ã®1.3åï¼ãããã ãã§ãã®ææè æ°ã®éããããã¨ãæãã¾ããã
大ããªéãã¯æ¿åºãèªæ²»ä½ã®ä»å ¥ã®å·®ãããã¾ããæ¿åºã¯ä»å¹´1æ9æ¥ããã®æ²ç¸ãå±±å£ãåºå³¶ã®3çãç®åãã«ã¾ã延鲿¢çéç¹æªç½®ãé©ç¨ããæçµçã«å¯¾è±¡å°åã¯36é½éåºçã¾ã§æ¡å¤§ãã¾ãããå ãã¦çã«ãã£ã¦ã¯éå¸¸äºæ 宣è¨ãçºåºããã¾ãããä»å ¥ã®å¹æãå®ãã§ãªãã¨è¨ããããããã®æªç½®ã§ããããããçºåºããããã¨ã«ãã人ã ã®è¡åå¤å®¹ãè¡åèªç²ã«å¤å°ãªãã¨ãå½±é¿ããå¯è½æ§ãããã¾ãã
ããã第7æ³¢ã§ã¯ä½ãè¡åå¶éããªãããã§ããããã¦ã¤ã«ã¹ã«åºãã£ã¦ä¸ããã¨ãããããªãã®ã§ããåå°ã§å¤§è¦æ¨¡é³æ¥½ã³ã³ãµã¼ããè±ç«å¤§ä¼ããç¥ãã®ã¤ãã³ããéå¬ãããææãåºãã£ããã¨ãã¡ãã»ããã¥ã¼ã¹ã«ãªã£ã¦ãã¾ããææè ãã§ãªãæ¹ãããããããã§ãéã«ãã¥ã¼ã¹ã«ãªããªãæ¹ã追跡ä¸ä½çºãæ å ±é è½ãçã£ã¦ãã¾ãã¾ããä»ã¯å»çè² è·ã極åé¿ããªããã°ãããªãã®ã«ãçµæã¨ãã¦ãããã®éæ¥å¸¸çæ´»åã追ãè² è·ãããããã¨ã«ãªã£ã¦ãã¾ãã
è¥å¹´ä¸ä»£ã§ææãèå»¶ããããããªã¹ã¯ãé«ãé«é½¢è ã«ä¼ãã£ã¦ããã¨ãããã¨ãèããã°ããããã®ã¤ãã³ãã®ä¸æ¢ã縮å°è¦æ¨¡éå¬ã人ã ã®çå¤ç§»åãªã©ã®èªç²ãæ¿åºããã³ãããææ®µããã£ãã®ã§ã¯ãªããã¨æããã¾ãï¼ãã¡ããç·æ¥äºæ 宣è¨ã®çºåºã¨ããæãããããã§ããï¼ãä»è·æ½è¨ãé«é½¢è æ½è¨ãªã©ã«ããããµã¼ãã¤ã©ã¤ã³ã¹ãé«é½¢è ãåå± ããå®¶åºã«å¯¾ããæ³¨æåèµ·ãªã©ããããã§ã対çãã¨ããã¨ãã§ããã¯ãã§ãããããããã£ã¦ãããã¨ã¯ãéå¤ã§ã¯ãã¹ã¯ãå¤ãã¾ããããã¨ãã大ãã£ã³ãã¼ã³ã§ãã
åé½éåºçã®ç¥äºã®å¯¾å¿ãããããã§ãã第6æ³¢ã§ç ç²è ãç¶åºããçµé¨ãå ¨ãçãããã¦ãã¾ããããã¨ãã°ã大éªåºã¯ã第6æ³¢æµè¡ã®éã診æããæ»äº¡ã¾ã§ã®æéã徿¥ã«æ¯ã¹ã¦çããªã£ã¦ãããã¨ãå ±åãã¾ããï¼âçæéã§ã®é篤åã»è´æ»ã¯ãªãã¯ãã³ã®ç¹å¾´ï¼âãã®ï¼ï¼ãã徿¥ã®åºæºã§è¨ãéçåã®ããã»ã¹ãçµãªãã§äº¡ããªã£ã¦ãã人ãå¤ããã¨ã示åãã¦ãã¾ãããåææ´æç¥äºãè¨è ä¼è¦ã§ããã«è§¦ãã¦ãã¾ãããã«ããããããã大éªåºã¯ç¬¬7æ³¢ã§ã¾ãåããã¨ãç¹°ãè¿ãã夿°ã®ç ç²è ãåºãã¦ãã¾ãã
ããã¦ãå ¨å½ç¥äºä¼ãå»å¸«ä¼ãªã©ããåºã¦ãã声ã¨è¨ãã°ãããã«ãã¦æææ¡å¤§ãæãããã¨ãããã¨ã§ã¯ãªãããã®èº«æ¿ããã¨ãã¦ã2é¡ç¸å½è¦ç´ããã¨ããå ¨æ°ææ¡è¦ç´ããã¨ããã«ã¼ã«å¤æ´ã«é¢ãããã¨ã°ããã§ãã
2-4. ã¡ãã£ã¢ã®ååå ±éã¼è±å½ã®ä¾
æ¥æ¬ã®ãã¬ãã®ååå ±éããããã¬ã³ã風ã®å ±éã¯ãæ¿åºãçºæ¿è ã®ã³ãã対çã®ä¸ä½çºã徿¼ãããå½¢ã«ãªã£ã¦ãã¾ããæ®æ®µãããã³ããã¨å ±åãã¨ããã³ããã¨ã®å ±çããªã©ã®ãã¬ã¼ãºãçãã«ä½¿ããªãããã¦ã£ãºã³ããã®ä¸å¹³çãªã¹ã¯ã¨ããæ¬è³ªãè¦ããªããããè² ã®å½¹å²ãæããã¦ããã¨è¨ãã¾ãã
æ¨æ¥ã®ãã¬ãææ¥ãå ±éã¹ãã¼ã·ã§ã³ãã§ãè±å½ã®ç¹æ´¾å¡ã®å ±åãåãä¸ãã叿°ã¯ããã¹ã¯ããã¦ããªãããã風éªã®ãããªãã®ãã¨è¨ã£ã¦ãããã³ããåã®æ¥å¸¸ãåãæ»ãã¦ãããã¨ããä¼ãæ¹ã§ãè¦è´è ã®å±æ©æãç·©åããã®ã«ååãªå 容ã§ããã
è±å½ã®å®æ ã¯ãæ¥æ¬ã®ã¡ãã£ã¢å ±éã¨ã¯ããé¢ãããã®ã§ããããã§ãæ¢åºè¨äºãæç®ãç¾å°å°éå®¶ããã®ã¡ã¼ã«æ å ±ãªã©ãåèã«ããªããããã詳ããè±å½ã®ç¾ç¶ãç´¹ä»ãããã¨æãã¾ãã
è±å½ã§ã¯ä»å¹´ã®2æã«è¦å¶ãå ¨é¢è§£é¤ã¨ãªãã¾ããããããã¯ç§å¦çæ ¹æ ã«åºã¥ãã¨ãããããã彿°ã®ä¸è«åãã«ãªãããçºæ¿è ã®æ¿æ²»å¤æãè²æ¿ãã«ãã¿åºããã®ã§ããå ¨é¢è§£é¤ã¨ã¨ãã«å ¨æ°ææ¡ããªãããªããªãï¼ãµã³ãã«èª¿æ»ã®ã¿ï¼ã彿°ã¯æµè¡ç¶æ³ãç¥ããã¨ããªããªãã¾ããã
ããã¦ããã¨ãã¨ãã¹ã¯çç¨ã®ç¿æ £ããªã彿°ã¯è¦å¶ããããã¨ãå«ããããããè§£é¤ããããã¨ã§ããããæµè¡åã®å¹³æã«æ»ã£ãããã«é¯è¦ããè¦ããã®èªç±ã謳æããç½¹ã£ã¦ãã風éªã¿ãããªãã®ã ãã¨æ¯ãèã£ã¦ããã«ããã¾ãããææã®å®æ ã¨ç¤¾ä¼çæªå½±é¿ã¯ã¾ã£ããå¥åé¡ã§ãããå³1ã®ããã«ãå é²å½ã®ä¸ã§ãé«ãæ»äº¡çã«ãªã£ã¦ç¾ãã¦ããã®ã§ãã
ã¸ã§ã³ã½ã³é¦ç¸ã¯ãã¯ã¯ãã³æ¥ç¨®ããã°ã©ã ã®æåããªãã¯ãã³ã®æ³¢ãå»ã£ããã¨ãã¤ã³ã°ã©ã³ãã§COVID-19ã«ææãã¦å ¥é¢ããäººã®æ°ã1ä¸äººãä¸åãæ¸å°ãã¦ãããã¨ãææã¨éçåã¨ã®é¢é£ããããªãå¼±ã¾ã£ãããã¨ããå ¨é¢è§£é¤æªç½®ãå¯è½ã«ããã¨è¿°ã¹ã¾ãã [1]ãããã¦çµè²»é¢ã«ãè¨åãã¦ãããæ¤æ»ã»ãã¬ã¼ã·ã³ã°ã»éé¢ã®ä½å¶ã¯ãææ°ã®ä¼è¨å¹´åº¦ã§157åãã³ãã®è²»ç¨ãããã£ã¦ããã縮å°ããªããã°ãªããªãã¨ä¸»å¼µãã¾ããã
ããããããã¯ä¸è¿°ããããã«ã彿°ä¸è«ã峿¹ã«ãããã¨ã«åã®ããã«ãªã£ãæ¿æ²»å¤æã§ãããã¨ã¯æããã§ãããã¸ã§ã³ã½ã³æ°ã¨å½¼ã®ã¢ããã¤ã¶ã¼ã®éã®æºãææããã¦ãã¾ããå ¨é¢è¦å¶è§£é¤ã®å½æãä¾ç¶ã¨ãã¦ææè ãå¤ããéé¢ãææ°ãææ´ããå¯é空éã§ã®ãã¹ã¯çç¨ãªã©ã®å ¬è¡è¡ç対çãç¶æããå¿ è¦ããããã¨ãã¢ããã¤ã¶ã¼å¼·èª¿ãã¦ãã¾ãã [1]ãããã¦ããã¹ã¦ã®è¦å¶ãè§£é¤ããåã«ææè æ°ããã£ã¨å°ãªããªããã¨ãæã¾ãã¦ãã¾ããã
è±æ¿åºã®å ¨é¢è§£é¤ã®æ±ºå®ã«å¯¾ãã¦ã3,360人以ä¸ã®ç§å¦è ãå»å¸«ããã¤ã³ã°ã©ã³ãã®ã¯ãªã¹ã»ã¦ã£ãã£æé«å»å¦è²¬ä»»è ã¨ãããªãã¯ã»ãã©ã³ã¹è±å½æé«ç§å¦é¡§åã«å®ã¦ãå ¬éæ¸ç°¡ã«ç½²åããæ¿åºã®æ±ºå®ã®æ ¹æ ãæããã«ããããæ±ãã¾ãã [1]ããã®æ¿åºã®æ¹éããã¦ã¤ã«ã¹ã®å¾ªç°ãæ¡å¤§ããæ¸å¿µãã¹ãæ°åã¦ã¤ã«ã¹å¤ç°ä½ã®å¯è¦æ§ããªããå¯è½æ§ãããã¨ããæ¸å¿µãããããã§ãã
å°éå®¶ã屿§ããéããè±å½ã¯ã彿°ãç¥ããã¨ããªãæææµè¡ã®ç¶ç¶ã¨ã¨ãã«ãé·æã³ããçï¼long Covidï¼ã®å¢å ã¨å´åè ä¸è¶³ã¨ããæ°ããªåé¡ãæ±ãã¤ã¤ããã¾ã [4]ãè±å½ã®å ¬çå»çï¼NHSï¼ã¯ãã§ã«é·ãéç ´ç¶»ãã¦ãããæææ£è ãé·æã³ããçæ£è ã®å¢å ã¨ã¨ãã«ããã®ä»ã®æ ¢æ§ç¾æ£ã®æ£è ã®è¨ºçãæ²»çãæ»ãç¶æ ã«ãªã£ã¦ãã¾ããCOVID-19ææè ã¨é·æã³ããçã®äººã®å¢å ã¯ãè±å½ã®ã¿ãªããåå½ã®å ¬å ±ãµã¼ãã¹ã®å¤ãã®åéã§äººæä¸è¶³ãããããã¦ãããéµä¾¿äºæ¥ãå ¬å ±äº¤éæ©é¢ãèªç©ºäº¤éãããã¦ç·æ¥ãµã¼ãã¹ã«ãå½±é¿ãåºã¦ãã¾ã [5, 6]ã
ã¨ã¯ã»ã¿ã¼å¤§å¦å»å¦é¨ã®ããããã»ã¹ãã¬ã¤ã³ï¼David Strainï¼å士ã¯ããå ¥é¢ã¨æ»äº¡ã®ãªã¹ã¯ã®ã¿ã«åºã¥ãã¦Covidã管çããã¨ããæè¿ã®è±å½ã®æ¦ç¥ãèããã¨ãé·æã³ããçã®ç便°ãå¢å ãã¦ãããã¨ã¯å ¨ãé©ãã¹ããã¨ã§ã¯ãªããã¨è¿°ã¹ã¦ãã¾ã [4]ãé·æã³ããçãæ±ããã¾ã¾æ¾ç½®ããã人ã ã®æ°ããããããå¢ãç¶ããã ããã¨ææã§ããé·æã³ããçã§ã¯ãæ§å·®ãå¹´é½¢ã«ããå¤åãããã³å ç«ã¨å¼å¸å¨ã®å¥åº·ç¶æ ãçºçã«å½±é¿ãã¦ããå¯è½æ§ããããä½µåç¾æ£ã®å¤ãé«é½¢ã®å¤å´è ã¯ãç¹ã«æ¯æ´ãå¿ è¦ã¨ããã¨ããææãããã¾ã [7]ã
ãããã«
ç§ã¯äºã¶æåã®ããã°è¨äºï¼âãã®å¤ã®ç¬¬ï¼æ³¢ï¼æµè¡ï¼ã§ãã®å¤ã®ç¬¬7æ³¢æµè¡ãäºæ¸¬ãã以ä¸ã®ããã«è¿°ã¹ã¾ããã
é廿大ã®è¢«å®³ã¨ãªã£ã第6æ³¢ã®äºã®èã ãã«ã¯ãªã£ã¦ã»ããããã¾ãããããããæ·¡ã顿ã«çµããã§ãããããªããªãããã¯ãå½ã«ããææå¯¾çã®ä»å ¥ããªãæãè¡ãä»»ãã®ç¾ç¶ãæ¹åããã¦ããªãæ¤æ»ã»é²ç«ã·ã¹ãã ãåã®ããã®çµæ¸åªå ã®å§¿å¢ã彿°ã®é¦´ãã¨å«æ°ããæ¥ãæ°ã®ç·©ã¿ãªã©ãã伿åãå¢ããBA.5ã®ççºçææã許ãããã§ããããã¦ãææ¥å»çãå«ããå»çã²ã£è¿«ãå»çå´©å£ãç¹°ãè¿ãããã§ãããã
ããã¦ãä¸ã¶æåã®ããã°è¨äºï¼âç¬¬ï¼æ³¢æµè¡ã§ã®è¡åå¶éãªãã®ç¤¾ä¼å®é¨ï¼ã§ä»¥ä¸ã®ããã«è¿°ã¹ã¾ããã
è¥å¹´å±¤ã®ç æ°ã®"軽ã"ãåºæºã«ããã¨ãããã³ããã®æ¬è³ªï¼ä¸å¹³çãªã¹ã¯ï¼ãå¿ããå§¿å¢ãããã³æ¥æ¬ç¹æã®ä¸é½åãªæ¡ä»¶ãèããªãã§çµæ¸ãåã鏿ã¯ãææè ã¨æ£è ã大éçºçãããå»çãå§è¿«ãã第6波以ä¸ã®ç ç²è ãåºããã¨ã«ãªããããã¦å¤æ°ã®é·æã³ããçï¼long COVIDï¼ã®äººãã¡ãçããã¨ã«ãªãå¯è½æ§å¤§ã§ãã
ç§ãäºæ¸¬ããã¨ããã®ãã¨ãããã¾ç®ã®éã®ç¾å®ã¨ãã¦èµ·ããã¤ã¤ããã¾ãããããªç°¡åãªãã¨ããæ¿åºã¯äºæ¸¬ã§ããªãã£ãã®ã§ãããããã¾ã£ããç¡é²åã§ãããã¨ã«ãæ°ã¥ãããï¼ãããã¯æ°ã¥ãã¦ãã¦ãï¼ãã®ã¾ã¾ããéããããããæµè¡ã¯æ¸è¡°ããã¨ããèãã®æ¿æ¨©ã§ããããå³å»éé£ãé¡ããããã®ã§ãã
å¼ç¨æç®ã»è¨äº
[1] Limb, M.: Covid-19: Scientists and medics warn that it is too soon to lift all restrictions in England. BMJ 376, o469 (2022). https://doi.org/10.1136/bmj.o469 Â
[2] Yoshioka, E. et al.: Impact of the COVID-19 pandemic on suicide rates in Japan through December 2021: An interrupted time series analysis.Â
Lancet Reg. Health West. Pac. 24, 100480 (2022). https://doi.org/10.1016/j.lanwpc.2022.100480
[3] GLOBAL NOTE: ä¸çã®é«é½¢åçï¼é«é½¢è äººå£æ¯çï¼ å½å¥ã©ã³ãã³ã°ã»æ¨ç§». æ´æ°æ¥: 2022.07.29. https://www.globalnote.jp/post-3770.html
[4] Davis, N.: Two million people in UK living with long Covid, find studies The Guardian June 1, 2022. https://www.theguardian.com/world/2022/jun/01/two-million-people-in-uk-living-with-long-covid-say-studies
[5] Reuters: ã¢ã³ã°ã«ï¼è±çµæ¸ã«äººæä¸è¶³ã®æé²ãã³ããå¾éºçãEUé¢è±ã§. 2022.05.31. https://jp.reuters.com/article/analysis-britain-workforce-idJPKCN2ND09E
[6] Hofmann, F.: COVID numbers soar causing labor shortage. DW July 1, 2022. https://www.dw.com/en/covid-numbers-soar-causing-labor-shortage/a-62328357
[7] Thompson, E. I. et al.: Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat. Commun. 13, 3528 (2022). https://www.nature.com/articles/s41467-022-30836-0
å¼ç¨ããæèããã°è¨äº
2022å¹´8æ13æ¥Â ç±³CDCã¬ã¤ãã©ã¤ã³ã¨withã³ãã
2022å¹´8æ12æ¥ COVID-19ã¤ã³ãã¯ãã®æå°åã¼ç±³CDCã¬ã¤ãã©ã¤ã³
2022å¹´8æ8æ¥Â èµ·ããã¹ããã¦èµ·ãã£ãå»çå´©å£ãããã¦å°éå®¶æå¿æè¨ã®ç¡å³ä¹¾ç¥æ
2022å¹´7æ20æ¥ ç¬¬ï¼æ³¢æµè¡ã§ã®è¡åå¶éãªãã®ç¤¾ä¼å®é¨
2022å¹´6æ21æ¥ ãã®å¤ã®ç¬¬ï¼æ³¢ï¼æµè¡
2022å¹´3æ17æ¥Â çæéã§ã®é篤åã»è´æ»ã¯ãªãã¯ãã³ã®ç¹å¾´ï¼âãã®ï¼
ãããããããããããããããã  ããã
ã«ãã´ãªã¼ï¼ææçã¨COVID-19 (2022å¹´ï¼